SciVac Therapeutics Enters into Agreement to Acquire VBI Vaccines

CAMBRIDGE, MA and VANCOUVER, British Columbia, Oct. 26, 2015  -- VBI Vaccines Inc. (VBIV) ("VBI") and SciVac Therapeutics Inc. (VAC.TO) and (SVACF) ("SciVac") announced today that they have entered into an agreement and plan of merger (the "Agreement") under which SciVac has agreed to acquire VBI to form a commercial-stage company with a licensed hepatitis B ("HBV") vaccine and a pipeline of preventative and therapeutic vaccine candidates.

Pursuant to the Agreement, a newly-formed wholly owned subsidiary of SciVac will merge with and into VBI (the "Merger"), with VBI surviving the Merger as a wholly owned subsidiary of SciVac, and SciVac will change its name to VBI Vaccines Inc. At the effective time of the Merger, each share of VBI common stock will be converted into the right to receive 20.808356 common shares of SciVac (the "Exchange Ratio").

U.S. FDA Approves BELBUCA™ (buprenorphine) Buccal Film for Chronic Pain Management

New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility

DUBLIN and RALEIGH, N.C., Oct. 26, 2015  -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ:ENDP - News) (TSX:ENL.TO - News), and BioDelivery Sciences International, Inc. (NASDAQ:BDSI - News), announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA™ (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BELBUCA™, which is the first and only buprenorphine developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management, is expected to be commercially available in the U.S. during the first quarter of 2016 in seven dosage strengths, allowing for flexible dosing ranging from 75 micrograms to 900 micrograms every 12 hours. This enables physicians to individualize titration and treatment based on the optimally effective and tolerable dose for each patient. 

NeoGenomics signs Definitive Agreement to acquire Clarient, Inc.

GE Healthcare retains significant stake in NeoGenomics and Parties agree to collaborate on Bioinformatics Initiative

ORT MYERS, Fla., Oct. 21, 2015 -- NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, announced today that it has reached an agreement to acquire Clarient, Inc., and its wholly-owned subsidiary Clarient Diagnostic Services, Inc., a provider of comprehensive cancer diagnostic testing to hospitals, physicians and the pharmaceutical industry (together "Clarient").  Clarient, a unit of GE Healthcare's Life Sciences business, is based in Aliso Viejo, California and Houston, Texas and has approximately 415 employees.  Clarient had 2014 revenue of $127 million and Adjusted EBITDA⁽¹⁾ of approximately $13 million.

Keryx Biopharmaceuticals Announces $125 Million Private Placement of Convertible Senior Notes With The Baupost Group, L.L.C.

• Keryx implements plan to significantly reduce its annual cash operating expenses, beginning in 2016
• Increased cash position expected to take Auryxia™ (ferric citrate) franchise to cash flow positive

BOSTON, Oct. 15, 2015  -- Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that it has entered into an agreement to raise $125 million through the private placement of Convertible Senior Notes (the “Notes”), due 2020, with funds managed by The Baupost Group, L.L.C. With the additional capital, Keryx has a pro-forma cash position of approximately $225 million as of September 30, 2015. In conjunction with the financing, Keryx will increase the number of directors on its Board to eight, as Baupost will have the right to appoint a director to Keryx’s Board by the end of 2015. Baupost will also appoint an observer to Keryx’s board.